The effect of bariatric surgery on renal function and disease: A focus on outcomes and inflammation

Nephrology Dialysis Transplantation

Volumn 28, Issue SUPPL.4, 2013, Pages

  Neff, Karl J ^a   Frankel, Andrew H ^b   Tam, Frederick W K ^b   Sadlier, Denise M ^a   Godson, Catherine ^a   Le Roux, Carel W ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Albuminuria; Bariatric Surgery; Inflammation; Kidney disease; Proteinuria; Renal function

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE; CREATININE; CYTOKINE; GLUCAGON LIKE PEPTIDE 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SITAGLIPTIN; TUMOR NECROSIS FACTOR ALPHA;

BARIATRIC SURGERY; CHRONIC KIDNEY DISEASE; CHRONIC LOW GRADE INFLAMMATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC KIDNEY DISEASE; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; HISTOLOGY; HUMAN; HYPERGLYCEMIA; HYPEROXALURIA; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHRITIS; NEPHROLITHIASIS; NONHUMAN; OBESITY; OXALIC ACID NEPHROPATHY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; WEIGHT REDUCTION;

EID: 84890083319     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft262     Document Type: Review

References (109)

1. Bosma RJ, van der Heide JJ, Oosterop EJ et al. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 2004; 65: 259-265
2. Chagnac A, Weinstein T, Korzets A et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278: F817-822
3. Wang Y, Chen X, Song Y et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008; 73: 19-33
4. Kramer H, Reboussin D, Bertoni AG et al. Obesity and albuminuria among adults with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) Study. Diabetes Care 2009; 32: 851-853
5. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
6. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509
7. Praga M, Hernandez E, Morales E et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001; 16: 1790-1798
8. Collins AJ, Foley RN, Chavers B et al. United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis 2012; 59(1 Suppl 1): A7., e1-420
9. Luaces M, Martinez-Martinez E, Medina M et al. The impact of bariatric surgery on renal and cardiac functions in morbidly obese patients. Nephrol Dial Transplant 2012; 27(Suppl 4): iv53-iv7
10. Navaneethan SD, Yehnert H, Moustarah F et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 1565-15674
11. Meijer RI, van Wagensveld BA, Siegert CE et al. Bariatric surgery as a novel treatment for type 2 diabetes mellitus: a systematic review. Arch Surg 2011; 146: 744-750
12. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009; 19: 1605-1611
13. Fenske WK, Dubb S, Bueter M et al. Effect of bariatric surgeryinduced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis 2012 [Epub ahead of print]
14. Rao SR. Inflammatory markers and bariatric surgery: a metaanalysis. Inflamm Res 2012; 61: 789-807
15. Hofso D, Nordstrand N, Johnson LK et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol 2010; 163: 735-745
16. Navaneethan SD, Kelly KR, Sabbagh F et al. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg 2010; 20: 308-315
17. Amor A, Jimenez A, Moize V et al. Weight loss independently predicts urinary albumin excretion normalization in morbidly obese type 2 diabetic patients undergoing bariatric surgery. Surg Endosc 2013; 27: 2046-2051
18. Agrawal V, Khan I, Rai B et al. The effect of weight loss after bariatric surgery on albuminuria. Clin Nephrol. 2008; 70: 194-202
19. Miras AD, Chuah LL, Lascaratos G et al. Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care 2012; 35: e81
20. Getty JL, Hamdallah IN, Shamseddeen HN et al. Changes in renal function following Roux-en-Y gastric bypass: a prospective study. Obes Surg 2012; 22: 1055-1059
21. Michels WM, Grootendorst DC, Verduijn M et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010; 5: 1003-1009
22. Melloni C, Peterson ED, Chen AY et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2008; 51: 991-996
23. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
24. Park EJ, Pai MP, Dong T et al. The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. Ann Pharmacother 2012; 46: 317-328
25. Abouchacra S, Chaaban A, Gebran N et al. GFR estimation in the morbidly obese pre- and postbariatric surgery: one size does not fit all. Int Urol Nephrol 2013; 45: 157-162
26. Smith BR, Schauer P, Nguyen NT. Surgical approaches to the treatment of obesity: bariatric surgery. Med Clin North Am 2011; 95: 1009-1030
27. Pournaras DJ, Osborne A, Hawkins SC et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg 2010; 252: 966-971
28. Kashyap SR, Daud S, Kelly KR et al. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond) 2010; 34: 462-471
29. Papamargaritis DK, Pournaras DJ, le Roux CW. Techniques, assessment, and effectiveness of bariatric surgery in combating obesity. Open Access Surg 2010; 3: 123-136
30. Navarro-Diaz M, Serra A, Romero R et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006; 17(12 Suppl 3): S213-217
31. Hou CC, Shyu RS, Lee WJ et al. Improved renal function 12 months after bariatric surgery. Surg Obes Relat Dis 2013; 9: 202-206
32. Saliba J, Kasim NR, Tamboli RA et al. Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. Surgery 2010; 147: 282-287
33. Iaconelli A, Panunzi S, De Gaetano A et al. Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. Diabetes Care 2011; 34: 561-567
34. Nguyen NT, Masoomi H, Laugenour K et al. Predictive factors of mortality in bariatric surgery: data from the Nationwide Inpatient Sample. Surgery 2011; 150: 347-351
35. Turgeon NA, Perez S, Mondestin M et al. The impact of renal function on outcomes of bariatric surgery. J Am Soc Nephrol. 2012; 23: 885-894
36. Navaneethan SD, Yehnert H. Bariatric surgery and progression of chronic kidney disease. Surg Obes Relat Dis 2009; 5: 662-665
37. Jose B, Ford S, Super P et al. The effect of biliopancreatic diversion surgery on renal function-a retrospective study. Obes Surg 2013; 23: 634-637
38. Zalesin KC, McCullough PA. Bariatric surgery for morbid obesity: risks and benefits in chronic kidney disease patients. Adv Chronic Kidney Dis 2006; 13: 403-417
39. Alexander JW, Goodman HR, Gersin K et al. Gastric bypass in morbidly obese patients with chronic renal failure and kidney transplant. Transplantation 2004; 78: 469-474
40. Alexander JW, Goodman H. Gastric bypass in chronic renal failure and renal transplant. Nutr Clin Pract 2007; 22: 16-21
41. Buch KE, El-Sabrout R, Butt KM. Complications of laparoscopic gastric banding in renal transplant recipients: a case study. Transplant Proc 2006; 38: 3109-3111
42. Newcombe V, Blanch A, Slater GH et al. Laparoscopic adjustable gastric banding prior to renal transplantation. Obes Surg 2005; 15: 567-570
43. Huan Y, Tomaszewski JE, Cohen DL. Resolution of nephritic syndrome after successful bariatric surgery in patient with biopsy-proven FSGS. Clin Nephrol 2009; 71: 69-73
44. Alexander JW, Goodman HR, Hawver LR et al. Improvement and stabilization of chronic kidney disease after gastric bypass. Surg Obes Relat Dis 2009; 5: 237-241
45. Afshinnia F, Wilt TJ, Duval S et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 2010; 25: 1173-1183
46. Serra A, Granada ML, Romero R et al. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr 2006; 25: 400-408
47. Heneghan HM, Cetin D, Navaneethan SD et al. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis 2013; 9: 7-14
48. Newman DJ, Mattock MB, Dawnay AB et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9: 3-6, 13-163
49. Bueter M, Dubb SS, Gill A et al. Renal cytokines improve early after bariatric surgery. Br J Surg 2010; 97: 1838-1844
50. Canales BK, Reyes L, Reinhard MK et al. Renal glomerular and tubular injury after gastric bypass in obese rats. Nutrition 2012; 28: 76-80
51. Kasiske BL, Cangro CB, Hariharan S et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1(Suppl 2): 3-95
52. Heemann U, Abramowicz D, Spasovski G et al. European Renal Best Practice Work Group on Kidney T. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant 2011; 26: 2099-2106
53. Lentine KL, Delos Santos R, Axelrod D et al. Obesity and kidney transplant candidates: how big is too big for transplantation? Am J Nephrol 2012; 36: 575-586
54. Modanlou KA, Muthyala U, Xiao H et al. Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation 2009; 87: 1167-1173
55. Smith MD, Patterson E, Wahed AS et al. Thirty-day mortality after bariatric surgery: independently adjudicated causes of death in the longitudinal assessment of bariatric surgery. Obes Surg 2011; 21: 1687-1692
56. Reoch J, Mottillo S, Shimony A et al. Safety of laparoscopic vs open bariatric surgery: a systematic review and meta-analysis. Arch Surg 2011; 146: 1314-1322
57. Encinosa WE, Bernard DM, Chen CC et al. Healthcare utilization and outcomes after bariatric surgery.Med Care 2006; 44: 706-712
58. Durrani O, Morrisroe S, Jackman S et al. Analysis of stone disease in morbidly obese patients undergoing gastric bypass surgery. J Endourol 2006; 20: 749-752
59. Sinha MK, Collazo-Clavell ML, Rule A et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 2007; 72: 100-107
60. Duffey BG, Alanee S, Pedro RN et al. Hyperoxaluria is a longterm consequence of Roux-en-Y Gastric bypass: a 2-year prospective longitudinal study. J Am Coll Surg 2010; 211: 8-15
61. Nelson LG, Gonzalez R, Haines K et al. Amelioration of gastroesophageal reflux symptoms following Roux-en-Y gastric bypass for clinically significant obesity. Am Surg 2005; 71: 950-953; discussion 3-4
62. Nasr SH, D'Agati VD, Said SM et al. Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol 2008; 3: 1676-1683
63. Troxell ML, Houghton DC, Hawkey M et al. Enteric oxalate nephropathy in the renal allograft: an underrecognized complication of bariatric surgery. Am J Transplant 2013; 13: 501-509
64. Wu JN, Craig J, Chamie K et al. Urolithiasis risk factors in the bariatric population undergoing gastric bypass surgery. Surg Obes Relat Dis 2013; 9: 83-87
65. Whitson JM, Stackhouse GB, Stoller ML. Hyperoxaluria after modern bariatric surgery: case series and literature review. Int Urol Nephrol 2010; 42: 369-374
66. de Oliveira LD, Diniz MT, de Fatima HSDM et al. Rhabdomyolysis after bariatric surgery by Roux-en-Y gastric bypass: a prospective study. Obesity Surg 2009; 19: 1102-1107. PubMed PMID: 19096900
67. Youssef T, Abd-Elaal I, Zakaria G et al. Bariatric surgery: Rhabdomyolysis after open Roux-en-Y gastric bypass: a prospective study. Int J Surg 2010; 8: 484-488
68. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010; 3: 101-108
69. Ouchi N, Parker JL, Lugus JJ et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97
70. McDonald S, Maguire G, Duarte N et al. C-reactive protein, cardiovascular risk, and renal disease in a remote Australian Aboriginal community. Clin Sci (Lond) 2004; 106: 121-128
71. Illan-Gomez F, Gonzalvez-Ortega M, Orea-Soler I et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg 2012; 22: 950-955
72. Catalan V, Gomez-Ambrosi J, Ramirez B et al. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 2007; 17: 1464-1474
73. Pardina E, Ferrer R, Baena-Fustegueras JA et al. Only C-reactive protein, but not TNF-alpha or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg 2012; 22: 131-139
74. Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2011; 7: 618-624
75. Zhang H, Wang Y, Zhang J et al. Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2011; 31: 2063-2069
76. Dalmas E, Rouault C, Abdennour M et al. Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. Am J Clin Nutr 2011; 94: 450-458
77. Chow FY, Nikolic-Paterson DJ, Ma FY et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007; 50: 471-480
78. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294: F697-701
79. Wang X, Chen H, Zhang M et al. Roles of mast cells and monocyte chemoattractant protein-1 in the renal injury of obesityrelated glomerulopathy. Am J Med Sci. 2012 [Epub ahead of print]
80. Kanamori H, Matsubara T, Mima A et al. Inhibition of MCP-1/ CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007; 360: 772-777
81. Tarabra E, Giunti S, Barutta F et al. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009; 58: 2109-2118
82. Darisipudi MN, Kulkarni OP, Sayyed SG et al. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol 2011; 179: 116-124
83. Brown FG, Nikolic-Paterson DJ, Hill PA et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol 2002; 13(Suppl) 1: S7-13
84. Lan HY, Bacher M, Yang N et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997; 185: 1455-1465
85. Church TS, Willis MS, Priest EL et al. Obesity, macrophage migration inhibitory factor, and weight loss. Int J Obes (Lond) 2005; 29: 675-681
86. Monte SV, Caruana JA, Ghanim H et al. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery 2012; 151: 587-593
87. Hirsch FF, Pareja JC, Geloneze SR et al. Comparison of metabolic effects of surgical-induced massive weight loss in patients with long-term remission versus non-remission of type 2 diabetes. Obes Surg 2012; 22: 910-917
88. Wang Y, Harris DC. Macrophages in renal disease. J Am Soc Nephrol 2011; 22: 21-27
89. Duffield JS.Macrophages in kidney repair and regeneration. J Am Soc Nephrol 2011; 22: 199-201
90. Wada T, Furuichi K, Sakai N et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 2004; 15: 940-948
91. Sung SA, Jo SK, Cho WY et al. Reduction of renal fibrosis as a result of liposome encapsulated clodronate induced macrophage depletion after unilateral ureteral obstruction in rats. Nephron Exp Nephrol 2007; 105: e1-9
92. Wang Y, Wang YP, Zheng G et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007; 72: 290-299
93. Borgeson E, Godson C. Molecular circuits of resolution in renal disease. ScientificWorld J. 2010; 10: 1370-1385
94. Hogan AE, Tobin AM, Ahern T et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 2011; 54: 2745-2754
95. Kodera R, Shikata K, Kataoka HU et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978
96. Chow FY, Nikolic-Paterson DJ, Ozols E et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80
97. Cummings BP, Stanhope KL, Graham JL et al. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCDT2DM rats. Diabetes 2010; 59: 2653-2661
98. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM et al. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. J Mol Endocrinol 2008; 41: 35-44
99. Ahern T, Tobin AM, Corrigan M et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol 2012 [Epub ahead of print]
100. Hossler EW, Wood GC, Still CD et al. The effect of weight loss surgery on the severity of psoriasis. Br J Dermatol. 2013; 168: 660-661
101. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-340
102. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011; 58: 69-73
103. Brown DX, Evans M. Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: a pharmacological perspective. J Nutr Metab 2012; 2012: 381713
104. Mega C, de Lemos ET, Vala H et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011; 2011: 162092
105. Satoh-Asahara N, Sasaki Y, Wada H et al. A dipeptidyl peptidase- 4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013; 62: 347-351
106. Rizzo MR, Barbieri M, Marfella R et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-4 inhibition. Diabetes Care 2012; 35: 2076-2082
107. Shirakawa J, Fujii H, Ohnuma K et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60: 1246-1257
108. Pacheco BP, Crajoinas RO, Couto GK et al. Dipeptidyl peptidase 4 inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 2011; 29: 520-528
109. Tofovic DS, Bilan VP, Jackson EK. Sitagliptin augments angiotensin 2-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clin Exp Pharmacol Physiol 2010; 37: 689-691